Johan Askling
Karolinska University Hospital · 670 works · 31,393 citations · h-index 95
Top works
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
- Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis
- Decreased Survival of Subjects With Elevated Liver Function Tests During A 28-Year Follow-Up
- Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
- Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
- Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first‐degree relatives
- Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
- Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
- Family history as a risk factor for colorectal cancer in inflammatory bowel disease
- Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis
- Autoimmune and Chronic Inflammatory Disorders and Risk of Non-Hodgkin Lymphoma by Subtype
- Characteristics of Hodgkin's Lymphoma after Infectious Mononucleosis
- Increased Risk for Cancer Following Sarcoidosis
- Swedish registers to examine drug safety and clinical issues in RA
- Rheumatoid arthritis and malignant lymphomas
- Causes of Death in Patients With Celiac Disease in a Population-Based Swedish Cohort
- Adaptation of the Charlson Comorbidity Index for Register-Based Research in Sweden
- Risk of haematopoietic cancer in patients with inflammatory bowel disease
- Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta‐analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
- Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives